Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers…
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation…
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual…
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’…
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering Short Term Tranche Warrants Potentially…
Calidi Biotherapeutics Announces Proposed Public Offering
Calidi Biotherapeutics Announces Proposed Public Offering SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) — Calidi…